A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its ...

Merck has reported a string of setbacks in the development of cancer and multiple sclerosis drugs in recent years. The company however raised the mid-term outlook for its electronics division to a ...